Based on these results, the PACIFIC 8 phase III trial studies the effects of Durvalumab plus anti-TIGIT (Domvanalimab) as sequential therapy in participants with stage III NSCLC who have not progressed following definitive, platinum-based concurrent chemo-radiotherapy. The gene discussed is TIGIT; the disease is non-small cell lung carcinoma.